Introduction Selective serotonin reuptake inhibitors (SSRIs) and triptans are two widely prescribed classes of medications used for managing mental health disorders and migraines, respectively. While both have proven therapeutic benefits, their concurrent use can pose a significant risk: serotonin syndrome. This potentially life-threatening condition results from excessive serotonergic activity in the central nervous system. The interaction between SSRIs and triptans underscores the importance of understanding pharmacological synergies, identifying risk factors, and implementing proactive management strategies. Mechanism of Serotonin Syndrome Serotonin syndrome occurs when there is an overabundance of serotonin (5-HT) in the brain, particularly in the synaptic cleft. This hyper-serotonergic…